Skip to main content
Premium Trial:

Request an Annual Quote

A3P Biomedical, BioAgilytix Partner to Bring Prostate Cancer Test to US

NEW YORK – Swedish diagnostics firm A3P Biomedical announced on Wednesday that it has partnered with BioAgilytix to bring A3P's prostate cancer test to the US as a laboratory-developed test.

The Stockholm3 assay uses protein biomarkers, genetic biomarkers, clinical data, and a proprietary algorithm to predict the risk of aggressive prostate cancer at an early stage. The blood test was developed by scientists at Sweden's Karolinska Institutet, A3P Biomedical noted in a statement. 

"Our goal is to introduce Stockholm3 as an LDT that identifies men with increased risk of prostate cancer early and, at the same time, reduces unnecessary interventions," A3P Biomedical CEO David Rosén said in a statement. "The US market is one of the largest in the world and would clearly benefit from implementing prostate cancer diagnostics that improve men's health and quality of life."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.